Haemophilus influenzae type b (Hib) vaccines help prevent Haemophilus infections but not infections caused by other strains of H. influenzae bacteria. H. influenzae causes many childhood infections, including bacteremia, meningitis, pneumonia, sinusitis, otitis media, and epiglottitis.
(See also Overview of Immunization.)
Hib vaccines are prepared from the purified capsule of Haemophilus influenzae type b (Hib). All Hib vaccines use polyribosylribitol phosphate (PRP) as the polysaccharide, but 4 different protein carriers are used in the 4 different Hib conjugate vaccines available:
PRP-D and HbOC vaccines are no longer available in the US.
The Hib vaccine is a routine childhood vaccination (see Table: Recommended Immunization Schedule for Ages 0–6 Years).
This vaccine is also recommended for
Adults with anatomic or functional asplenia and those scheduled for elective splenectomy if they are unimmunized (ie, if they have not previously received a primary series plus booster dose or ≥ 1 dose of Hib vaccine after age 14 months), although some experts suggest giving a dose before elective splenectomy regardless of vaccination history
Immunocompromised adults (eg, because of cancer chemotherapy or HIV infection) if they are unimmunized
People who have had a hematopoietic stem cell transplantation regardless of their vaccination history
The main contraindication for Hib vaccines is
A severe allergic reaction (eg, anaphylaxis) after previous dose or to a vaccine component
The main precaution with Hib vaccines is
The Hib vaccine dose is 0.5 mL IM. A primary childhood series is given in 3 doses at age 2, 4, and 6 months or in 2 doses at age 2 and 4 months, depending on the formulation. In either case, a booster is recommended at age 12 to 15 months.
One dose is given to older children, adolescents, and adults who have asplenia or who are scheduled for an elective splenectomy if they are unimmunized. Some experts suggest giving a dose before elective splenectomy regardless of vaccination history. The dose is given ≥ 14 days before elective splenectomy if possible.
A 3-dose regimen is given 6 to 12 months after hematopoietic stem cell transplantation; doses are separated by ≥ 4 weeks.
The following are some English-language resources that may be useful. Please note that THE MANUAL is not responsible for the content of these resources.